Meeting
2022 ASCO Annual Meeting
Swallowing and quality-of-life outcomes of response adaptive de-escalated therapy following nivolumab-based induction for HPV+ oropharyngeal cancer.
Authors
Ari Rosenberg
University of Chicago, Department of Medicine, Chicago, IL
Ari Rosenberg , Alexander T. Pearson , Aditya Juloori , John Cursio , Zhen Gooi , Elizabeth A. Blair , Tanguy Y. Seiwert , Jeffrey Chin , Ellen MacCracken , Evgeny Izumchenko , Nishant Agrawal , Daniel J. Haraf , Everett E. Vokes
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT03107182
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 6011)
DOI
10.1200/JCO.2022.40.16_suppl.6011
Abstract #
6011
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.
First Author: Ari Rosenberg
Poster
2017 ASCO Annual Meeting
Optima: A phase II dose and volume de-escalation trial for high- and low-risk HPV+ oropharynx cancers.
First Author: James Melotek
Poster
2023 ASCO Annual Meeting
Are we ready for biomarker driven, radiation dose–adaptable de-escalation studies for HPV+ oropharyngeal cancer?
First Author: Krzysztof Misiukiewicz
Poster
2022 ASCO Annual Meeting
Nivolumab-based induction chemoimmunotherapy and PD-L1 expression in locoregionally advanced HPV-associated oropharyngeal squamous cell carcinoma.
First Author: Ari Rosenberg